-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, Biogen announced that it had completed the sale of Samsung Bioepis' shares to Samsung Biologics for up to $2.
In addition, the two companies will continue to execute the previously signed exclusive agreement, including the commercialization of the current portfolio (etanercept, adalimumab, infliximab)
In 2012, Samsung Bio and Biogen jointly funded the establishment of Samsung Bioepis, which mainly focuses on the development of biosimilars
Commercialization of the Alzheimer's drug Aduhelm has been hampered since its launch